Briacell Therapeutics CORP S-1 registration statements

BriaCell Therapeutics Corp. has filed an S-1MEF registration statement to offer up to $11.56 million in common units, pre-funded units, and associated warrants.

BriaCell Therapeutics Corp. files an S-1 registration statement for a best-efforts public offering of up to $25 million in common and pre-funded units to fund working capital and advance business objectives.

BriaCell Therapeutics Corp. has filed an S-1/A registration statement for a public offering of up to 6,825,938 common and pre-funded units, while reporting strong clinical data for its Bria-IMT and Bria-OTS immunotherapies in metastatic breast cancer.

BriaCell Therapeutics Corp. filed an S-1/A registration statement to offer up to 6,825,938 common units and pre-funded units, aiming to raise approximately $18.04 million to advance its clinical-stage cancer immunotherapies, Bria-IMT and Bria-OTS, which have shown promising survival and response rates in metastatic breast cancer.

BriaCell Therapeutics Corp. has filed an S-1 registration statement for a public offering of up to 6.8 million units to fund ongoing operations and advance its clinical-stage immunotherapy programs, following a series of positive clinical data readouts for its Bria-IMT and Bria-OTS candidates in metastatic breast cancer.

BriaCell Therapeutics Corp. is registering additional securities for a proposed maximum aggregate offering price not to exceed $5,318,750.

BriaCell Therapeutics is launching a firm commitment public offering of common units and pre-funded units to raise capital for working capital, general corporate purposes, and business objectives.

BriaCell Therapeutics launches a public offering of common and pre-funded units to bolster its clinical-stage immunotherapy programs.